MA27888A1 - Inhibiteurs de la kinase p38 a base d'heterocycles a 5 chainons - Google Patents
Inhibiteurs de la kinase p38 a base d'heterocycles a 5 chainonsInfo
- Publication number
- MA27888A1 MA27888A1 MA28678A MA28678A MA27888A1 MA 27888 A1 MA27888 A1 MA 27888A1 MA 28678 A MA28678 A MA 28678A MA 28678 A MA28678 A MA 28678A MA 27888 A1 MA27888 A1 MA 27888A1
- Authority
- MA
- Morocco
- Prior art keywords
- kinase
- kinase inhibitors
- inhibitors based
- heterocycles
- chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D231/52—Oxygen atom in position 3 and nitrogen atom in position 5, or vice versa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
Abstract
L'invention concerne des inhibiteurs de la kinase p38 à base d'hétérocycles à 5 chaînons. L'invention concerne en outre des inhibiteurs de la kinase p38, notamment de la kinase p38(alpha) et p38(bêta), à base de pyrazoles et d'imidazoles. L'invention concerne par ailleurs des compositions pharmaceutiques contenant ces composés, ainsi que des méthodes d'utilisation de ces composés et de ces compositions, notamment des méthodes visant à traiter, prévenir ou améliorer un ou plusieurs symptômes de maladies et de troubles à médiation par la kinase p38 comprenant, de façon non limitative, des maladies et des troubles inflammatoires.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48342803P | 2003-06-26 | 2003-06-26 | |
US49905403P | 2003-08-29 | 2003-08-29 | |
US56048104P | 2004-04-07 | 2004-04-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27888A1 true MA27888A1 (fr) | 2006-05-02 |
Family
ID=34108816
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28678A MA27888A1 (fr) | 2003-06-26 | 2005-12-21 | Inhibiteurs de la kinase p38 a base d'heterocycles a 5 chainons |
Country Status (27)
Country | Link |
---|---|
US (4) | US7863314B2 (fr) |
EP (2) | EP2298743B1 (fr) |
JP (1) | JP4838121B2 (fr) |
KR (1) | KR101120857B1 (fr) |
CN (1) | CN1832928B (fr) |
AT (1) | ATE517872T1 (fr) |
AU (1) | AU2004259662B2 (fr) |
BR (1) | BRPI0411825B8 (fr) |
CA (1) | CA2526455C (fr) |
CY (2) | CY1111985T1 (fr) |
DK (2) | DK1641764T3 (fr) |
EC (2) | ECSP056206A (fr) |
ES (1) | ES2393950T3 (fr) |
HK (2) | HK1149764A1 (fr) |
HR (2) | HRP20110757T1 (fr) |
IL (1) | IL172182A (fr) |
IS (2) | IS2916B (fr) |
MA (1) | MA27888A1 (fr) |
MX (1) | MXPA05013824A (fr) |
MY (1) | MY158162A (fr) |
NO (1) | NO334947B1 (fr) |
NZ (1) | NZ544230A (fr) |
PL (2) | PL1641764T3 (fr) |
PT (2) | PT1641764E (fr) |
SI (2) | SI1641764T1 (fr) |
TW (2) | TWI452035B (fr) |
WO (1) | WO2005009973A1 (fr) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7485657B2 (en) * | 2004-05-12 | 2009-02-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Anti-cytokine heterocyclic compounds |
NZ563003A (en) * | 2005-04-27 | 2011-03-31 | Univ Florida | Use of a farnesyl transferase inhibitor to enhance autophagic protein degradation in protein conformation disorders |
DE102005031580A1 (de) * | 2005-07-06 | 2007-01-11 | Aicuris Gmbh & Co. Kg | Substituierte Sulfolanylpyrazole und ihre Verwendung |
GB0603684D0 (en) * | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
CA2645856C (fr) | 2006-03-22 | 2011-09-20 | Kevin William Anderson | Pyrazoles utiles comme inhibiteurs de 11-beta-hsd-1 |
JP2009532495A (ja) * | 2006-04-03 | 2009-09-10 | ストワーズ インスティテュート フォー メディカル リサーチ | 多発性嚢胞腎の治療用の組成物及び治療方法 |
BRPI0717873A2 (pt) * | 2006-10-30 | 2013-10-29 | Novartis Ag | Derivado de 3-amino-pirazol-4-carboxamida úteis como inibidores de proteína quinases |
GB0621978D0 (en) * | 2006-11-03 | 2006-12-13 | Chroma Therapeutics Ltd | Inhibitors of p38 mitogen-activated protein kinase |
EP1992344A1 (fr) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha comme cible therapeutique pour les maladies associées á une mutation de FGFR3 |
US20090047243A1 (en) * | 2007-07-17 | 2009-02-19 | Richard Rickles | Combinations for the treatment of b-cell proliferative disorders |
AU2008276451A1 (en) * | 2007-07-17 | 2009-01-22 | Zalicus Inc. | Treatments of B-cell proliferative disorders |
WO2009012482A2 (fr) * | 2007-07-19 | 2009-01-22 | H.Lundbeck A/S | Amides heterocycliques a 5 chainons et composes associes |
WO2009085797A1 (fr) * | 2007-12-21 | 2009-07-09 | Gilead Sciences, Inc. | Procédés de préparation d'inhibiteurs de la transcriptase inverse du vih |
DE102008015033A1 (de) * | 2008-03-17 | 2009-09-24 | Aicuris Gmbh & Co. Kg | Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung |
US20090281150A1 (en) * | 2008-04-09 | 2009-11-12 | Nicola Frances Bateman | Compound 249 |
WO2009151569A2 (fr) * | 2008-06-09 | 2009-12-17 | Combinatorx, Incorporated | Agonistes des récepteurs bêta-adrénergiques utilisables pour le traitement des troubles prolifératifs des lymphocytes b |
ES2438496T3 (es) | 2008-08-01 | 2014-01-17 | Ventirx Pharmaceuticals, Inc. | Formulaciones de agonistas de receptores de tipo toll y su uso |
WO2010054215A1 (fr) | 2008-11-06 | 2010-05-14 | Ventirx Pharmaceuticals, Inc. | Procédés de synthèse de dérivés de benzazépine |
KR101529767B1 (ko) * | 2009-08-07 | 2015-06-17 | 추가이 세이야쿠 가부시키가이샤 | 아미노피라졸 유도체 |
WO2011022508A2 (fr) | 2009-08-18 | 2011-02-24 | Ventirx Pharmaceuticals, Inc. | Benzoazépines substituées comme modulateurs des récepteurs de type toll |
US8524702B2 (en) | 2009-08-18 | 2013-09-03 | Ventirx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
WO2011038261A1 (fr) * | 2009-09-24 | 2011-03-31 | Selexagen Therapeutics, Inc. | Inhibiteurs hétérocycliques de la kinase |
WO2011100769A2 (fr) * | 2010-02-15 | 2011-08-18 | Synovo Gmbh | Modulateurs de kinase pour le traitement du cancer |
SI2619182T1 (sl) * | 2010-09-21 | 2017-03-31 | Eisai R&D Management Co., Ltd. | Farmacevtski sestavek |
US8993631B2 (en) | 2010-11-16 | 2015-03-31 | Novartis Ag | Method of treating contrast-induced nephropathy |
EP2460519A1 (fr) * | 2010-12-03 | 2012-06-06 | Laboratorios Del. Dr. Esteve, S.A. | Utilisation de ligands sigma pour la douleur du cancer des os |
JP5620417B2 (ja) * | 2011-02-07 | 2014-11-05 | 中外製薬株式会社 | アミノピラゾール誘導体を含む医薬 |
DK2827860T3 (en) * | 2012-03-20 | 2016-12-12 | Mereo Biopharma 1 Ltd | USE OF A pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease |
WO2015084936A1 (fr) * | 2013-12-04 | 2015-06-11 | The Scripps Research Institute | Nouveaux composés utilisables en tant qu'inhibiteurs des janus kinases |
RU2653500C2 (ru) | 2013-12-13 | 2018-05-10 | Ф. Хоффманн-Ля Рош Аг | Ингибиторы тирозинкиназы брутона |
WO2015086635A1 (fr) | 2013-12-13 | 2015-06-18 | F. Hoffmann-La Roche Ag | Inhibiteurs de la tyrosine kinase de bruton |
DK3087986T3 (da) | 2013-12-27 | 2019-12-02 | Chugai Pharmaceutical Co Ltd | Mutant fgfr-gatekeepergen og aktivt stof rettet mod samme |
WO2016204261A1 (fr) | 2015-06-17 | 2016-12-22 | 中外製薬株式会社 | Dérivés d'aminopyrazole |
WO2017028816A1 (fr) * | 2015-08-20 | 2017-02-23 | 浙江海正药业股份有限公司 | Dérivé d'indole, son procédé de préparation et son utilisation dans un médicament pharmaceutique |
WO2017153701A1 (fr) | 2016-03-08 | 2017-09-14 | Mereo Biopharma 1 Limited | Régime posologique pour le traitement d'exacerbations aiguës d'états inflammatoires |
RU2713203C1 (ru) * | 2016-03-08 | 2020-02-04 | Мерео Байофарма 1 Лимитед | Режим дозирования при лечении острых обострений хронической обструктивной болезни легких |
GB201612240D0 (en) * | 2016-07-14 | 2016-08-31 | Mereo Biopharma 1 Ltd | Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide |
GB201612238D0 (en) * | 2016-07-14 | 2016-08-31 | Mereo Biopharma 1 Ltd | Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-Yl]-n-cyclopropyl-4-methylbenzamide |
WO2018059533A1 (fr) * | 2016-09-29 | 2018-04-05 | 南京明德新药研发股份有限公司 | Inhibiteur de la p38α mapk kinase, son procédé de préparation et son utilisation |
US11291680B2 (en) | 2016-12-15 | 2022-04-05 | Société des Produits Nestlé S.A. | Compositions and methods that modulate white blood cells or neutrophils in a companion animal |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
AU2018346712B2 (en) | 2017-10-05 | 2021-04-01 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
EP3585383B1 (fr) | 2017-12-11 | 2021-03-24 | Mereo BioPharma 1 Limited | Utilisation de 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide pour la prévention d'exacerbations aiguës d'une maladie pulmonaire obstructive chronique |
CA3085545A1 (fr) | 2017-12-11 | 2019-06-20 | Mereo Biopharma 1 Limited | Utilisation de 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide dans le traitement des exacerbations aigues de la bronchopneumopathie chronique obstruct ive |
JP2021519334A (ja) | 2018-03-26 | 2021-08-10 | クリア クリーク バイオ, インコーポレイテッド | ジヒドロオロト酸デヒドロゲナーゼを阻害するための組成物および方法 |
EP3563848A1 (fr) * | 2018-04-30 | 2019-11-06 | S.I.S.S.A. Scuola Internazionale Superiore di Studi Avanzati | Inhibiteurs de la serpine pour le traitement des maladies à prions et de type prion |
GB201815696D0 (en) * | 2018-09-26 | 2018-11-07 | Mereo Biopharma 1 Ltd | Synthetic method |
GB201815695D0 (en) | 2018-09-26 | 2018-11-07 | Mereo Biopharma 1 Ltd | Synthetic method |
GB201815699D0 (en) * | 2018-09-26 | 2018-11-07 | Mereo Biopharma 1 Ltd | Synthetic method |
CN110950848B (zh) * | 2018-09-27 | 2024-03-26 | 徐诺药业 | 新型氨基吡唑类衍生物的合成与应用 |
US20230025630A1 (en) * | 2018-11-13 | 2023-01-26 | Novartis Ag | Compounds and compositions for treating conditions associated with nlrp activity |
CN112778333B (zh) * | 2021-01-23 | 2022-07-05 | 中国科学院新疆理化技术研究所 | 一种四氢噁唑并吡啶并氮氧杂酮类衍生物及其用途 |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1152421B (de) | 1961-03-21 | 1963-08-08 | Bayer Ag | Verfahren zur Herstellung von 4-Hydroxy-pyrazolo[3, 4-b]chinolinen |
JPS5111499Y2 (fr) | 1971-04-22 | 1976-03-27 | ||
USRE28819E (en) * | 1972-12-08 | 1976-05-18 | Syntex (U.S.A.) Inc. | Dialkylated glycol compositions and medicament preparations containing same |
JPS5527916B2 (fr) | 1973-02-05 | 1980-07-24 | ||
JPS51112341A (en) | 1975-02-24 | 1976-10-04 | Konishiroku Photo Ind Co Ltd | Magenta dye image formation |
US4200750A (en) | 1977-01-07 | 1980-04-29 | Westwood Pharmaceuticals Inc. | 4-Substituted imidazo [1,2-a]quinoxalines |
WO1994013643A1 (fr) | 1992-12-17 | 1994-06-23 | Pfizer Inc. | Pyrazoles et pyrazolopyrimidines presentant une activite d'antagonistes du facteur de liberation de la cortitrophine |
US6103900A (en) | 1992-12-17 | 2000-08-15 | Pfizer Inc | Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity |
US6005109A (en) | 1997-10-30 | 1999-12-21 | Pflizer Inc. | Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity |
US5514643A (en) | 1993-08-16 | 1996-05-07 | Lucky Ltd. | 2-aminothiazolecarboxamide derivatives, processes for preparing the same and use thereof for controlling phytopathogenic organisms |
US5646152A (en) | 1994-06-15 | 1997-07-08 | Pfizer Inc. | Methods of administering CRF antagonists |
CA2163399A1 (fr) | 1994-11-24 | 1996-05-25 | Katsuhiro Kawano | Derives de la triazine, inhibiteurs de l'activite de la chymase et de la production d'oxyde nitrique |
DE19518054A1 (de) | 1995-03-08 | 1996-09-12 | Hoechst Schering Agrevo Gmbh | N-Arylpyrazolketone und deren Derivate, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel |
US5658903A (en) | 1995-06-07 | 1997-08-19 | Smithkline Beecham Corporation | Imidazole compounds, compositions and use |
AU715900B2 (en) | 1996-01-11 | 2000-02-10 | Smithkline Beecham Corporation | Novel substituted imidazole compounds |
US5945418A (en) | 1996-12-18 | 1999-08-31 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
US6147080A (en) | 1996-12-18 | 2000-11-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
EP0946508B1 (fr) | 1996-12-23 | 2009-09-23 | Bristol-Myers Squibb Pharma Company | COMPOSES HETEROAROMATIQUES CONTENANT DE L'AZOTE, UTILISES EN TANT QU'INHIBITEURS DU FACTEUR Xa |
US6087496A (en) | 1998-05-22 | 2000-07-11 | G. D. Searle & Co. | Substituted pyrazoles suitable as p38 kinase inhibitors |
BR9809451A (pt) | 1997-05-22 | 2000-06-20 | Searle & Co | Pirazóis substituìdos com 3(5)-heteroarila como inibidores de quinase p38. |
EP1019396A1 (fr) | 1997-07-02 | 2000-07-19 | SmithKline Beecham Corporation | Nouveaux imidazoles cycloalkyle-substitues |
ATE332896T1 (de) | 1997-10-27 | 2006-08-15 | Agouron Pharma | 4-aminothiazol derivate, deren herstellung und deren verwendung als inhibitoren cyclin- abhängiger kinasen |
IL139169A0 (en) * | 1998-05-05 | 2001-11-25 | Hoffmann La Roche | Pyrazole derivatives as p-38 map kinase inhibitors |
US20020156114A1 (en) | 1998-05-05 | 2002-10-24 | Goldstein David Michael | Pyrazole derivatives - p38 MAP kinase inhibitors |
US6376527B1 (en) | 1998-05-05 | 2002-04-23 | Syntex (U.S.A.) Llc | Pyrazole derivatives-p38 map kinase inhibitors |
US6316466B1 (en) * | 1998-05-05 | 2001-11-13 | Syntex (U.S.A.) Llc | Pyrazole derivatives P-38 MAP kinase inhibitors |
US6130235A (en) | 1998-05-22 | 2000-10-10 | Scios Inc. | Compounds and methods to treat cardiac failure and other disorders |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
US6410540B1 (en) | 1998-08-28 | 2002-06-25 | Scios, Inc. | Inhibitors of p38-αkinase |
AU764479B2 (en) | 1998-10-29 | 2003-08-21 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme |
GB9906566D0 (en) | 1999-03-23 | 1999-05-19 | Zeneca Ltd | Chemical compounds |
RU2260592C9 (ru) | 1999-04-15 | 2017-04-07 | Бристол-Маерс Сквибб Ко. | Циклические ингибиторы протеинтирозинкиназ |
GB9924092D0 (en) | 1999-10-13 | 1999-12-15 | Zeneca Ltd | Pyrimidine derivatives |
ES2237470T3 (es) | 1999-11-10 | 2005-08-01 | Ortho-Mcneil Pharmaceutical, Inc. | 2-aril-3-(heteroaril)-imidazo(1,2-alfa)pirimidinas sustituidas; y composiciones farmaceuticas y procedimientos asociados. |
AU2001230026A1 (en) | 2000-02-04 | 2001-08-14 | Novo-Nordisk A/S | 2,4-diaminothiazole derivatives |
HUP0303038A2 (hu) | 2000-09-21 | 2003-12-29 | Bristol-Myers Squibb Co. | Szubsztituált azolszármazékok mint kortikotropin releasing faktor inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk |
AU2002232760B2 (en) | 2000-11-17 | 2006-12-14 | Bristol-Myers Squibb Company | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
AU2002219678A1 (en) | 2001-01-17 | 2002-07-30 | Boyean Kim | Sun visor having office work apparatus |
US6756374B2 (en) | 2001-01-22 | 2004-06-29 | Hoffmann-La Roche Inc. | Diaminothiazoles having antiproliferative activity |
US7271181B2 (en) | 2001-05-11 | 2007-09-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
HN2002000156A (es) | 2001-07-06 | 2003-11-27 | Inc Agouron Pharmaceuticals | Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización. |
GB0124936D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124938D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124933D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124941D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124928D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124934D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124931D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124939D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124932D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0217757D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Novel compounds |
BRPI0418112A (pt) * | 2003-12-23 | 2007-04-17 | Novartis Ag | inibidores de p-38 quinase bicìclico heterocìclicos |
JP2007084437A (ja) | 2003-12-26 | 2007-04-05 | Dai Ichi Seiyaku Co Ltd | アミノアルキルピラゾール誘導体 |
-
2004
- 2004-06-24 AT AT04777075T patent/ATE517872T1/de active
- 2004-06-24 NZ NZ544230A patent/NZ544230A/en unknown
- 2004-06-24 CN CN2004800180564A patent/CN1832928B/zh active Active
- 2004-06-24 SI SI200431766T patent/SI1641764T1/sl unknown
- 2004-06-24 WO PCT/US2004/020384 patent/WO2005009973A1/fr active Application Filing
- 2004-06-24 PT PT04777075T patent/PT1641764E/pt unknown
- 2004-06-24 MX MXPA05013824A patent/MXPA05013824A/es active IP Right Grant
- 2004-06-24 EP EP10164367A patent/EP2298743B1/fr active Active
- 2004-06-24 CA CA2526455A patent/CA2526455C/fr active Active
- 2004-06-24 DK DK04777075.5T patent/DK1641764T3/da active
- 2004-06-24 EP EP04777075A patent/EP1641764B1/fr active Active
- 2004-06-24 KR KR1020057024679A patent/KR101120857B1/ko active IP Right Grant
- 2004-06-24 TW TW093118259A patent/TWI452035B/zh not_active IP Right Cessation
- 2004-06-24 JP JP2006517650A patent/JP4838121B2/ja active Active
- 2004-06-24 PT PT101643674T patent/PT2298743E/pt unknown
- 2004-06-24 DK DK10164367.4T patent/DK2298743T3/da active
- 2004-06-24 BR BRPI0411825A patent/BRPI0411825B8/pt not_active IP Right Cessation
- 2004-06-24 AU AU2004259662A patent/AU2004259662B2/en active Active
- 2004-06-24 TW TW100114024A patent/TWI449696B/zh not_active IP Right Cessation
- 2004-06-24 ES ES10164367T patent/ES2393950T3/es active Active
- 2004-06-24 PL PL04777075T patent/PL1641764T3/pl unknown
- 2004-06-24 SI SI200431950T patent/SI2298743T1/sl unknown
- 2004-06-24 PL PL10164367T patent/PL2298743T3/pl unknown
- 2004-06-25 US US10/877,534 patent/US7863314B2/en active Active
- 2004-06-25 MY MYPI20042496A patent/MY158162A/en unknown
-
2005
- 2005-11-24 IL IL172182A patent/IL172182A/en active IP Right Grant
- 2005-12-08 EC EC2005006206A patent/ECSP056206A/es unknown
- 2005-12-21 MA MA28678A patent/MA27888A1/fr unknown
-
2006
- 2006-01-23 IS IS8255A patent/IS2916B/is unknown
- 2006-01-26 NO NO20060424A patent/NO334947B1/no unknown
- 2006-08-16 HK HK11107635.3A patent/HK1149764A1/xx not_active IP Right Cessation
- 2006-08-16 HK HK06109122.6A patent/HK1088895A1/xx unknown
-
2010
- 2010-11-19 US US12/950,649 patent/US8242117B2/en active Active
-
2011
- 2011-10-18 HR HR20110757T patent/HRP20110757T1/hr unknown
- 2011-10-27 CY CY20111101022T patent/CY1111985T1/el unknown
-
2012
- 2012-02-07 EC ECSP12006206 patent/ECSP12006206A/es unknown
- 2012-06-22 US US13/530,919 patent/US8410160B2/en active Active
- 2012-11-08 CY CY20121101064T patent/CY1113313T1/el unknown
- 2012-11-08 HR HRP20120900TT patent/HRP20120900T1/hr unknown
-
2013
- 2013-02-25 US US13/775,963 patent/US8580838B2/en active Active
-
2014
- 2014-01-28 IS IS9037A patent/IS2984B/is unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27888A1 (fr) | Inhibiteurs de la kinase p38 a base d'heterocycles a 5 chainons | |
BRPI0410905A (pt) | inibidores de p-38 | |
WO2005063766A3 (fr) | Inhibiteurs heterocycliques bicycliques des kinases p-38 | |
DK1333833T3 (da) | Ny trisubstitueret 8H-pyridol[2,3-d]pyrimidin-7-on-forbindelse til behandling af CSBP/RK/p38-kinnasemedierede sygdomme | |
CY2013041I1 (el) | Φαρμακευτικες συνθεσεις περιλαμβανοντας δεξτρομεθορφανη και κινιδινη για την αγωγη νευρολογικων διαταραχων | |
NO20053077D0 (no) | Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer. | |
UA85597C2 (ru) | Четвертичные соли как антагонисты ccr2 | |
ATE402176T1 (de) | Pyrrolidin- und azetidinverbindungen alsccr5- antagonisten | |
ATE463491T1 (de) | Indolylmaleimid derivate | |
ATE311389T1 (de) | Wirkstoffvorläufer von imidazopyridin-derivaten | |
ITMI20022594A1 (it) | Combinazione terapeutica per la cura dell'ipertensione. |